You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 14, 2026

Drug Price Trends for FT CLEARLAX POWDER


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for FT CLEARLAX POWDER

Average Pharmacy Cost for FT CLEARLAX POWDER

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
FT CLEARLAX POWDER 70677-1109-02 0.02417 GM 2026-02-18
FT CLEARLAX POWDER 70677-1068-01 0.02417 GM 2026-02-18
FT CLEARLAX POWDER 70677-1109-03 0.01999 GM 2026-02-18
FT CLEARLAX POWDER 70677-1068-02 0.01999 GM 2026-02-18
FT CLEARLAX POWDER 70677-1109-01 0.02954 GM 2026-02-18
FT CLEARLAX POWDER 70677-1109-02 0.02467 GM 2026-01-21
FT CLEARLAX POWDER 70677-1109-04 0.02429 GM 2026-01-21
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for FT ClearLax Powder

Last updated: February 23, 2026

What is the Market Size for OTC Laxatives Like FT ClearLax Powder?

The global over-the-counter (OTC) laxatives market, including products like FT ClearLax Powder, is valued at approximately USD 1.8 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.5% between 2023 and 2028. The primary drivers include increasing awareness of digestive health, aging populations, and rising prevalence of constipation.

Key regions contributing to this growth:

  • North America: 45% market share, driven by high health awareness and OTC product usage.
  • Europe: 25%, influenced by aging demographics.
  • Asia-Pacific: 20%, with rapid urbanization and rising healthcare spending.
  • Rest of World: 10%.

Competitive Dynamics and Key Players

Major manufacturers in the OTC laxatives segment include:

  • Johnson & Johnson (Kinderlyte, Fleet)
  • Bayer Healthcare
  • Sanofi (Dulcolax)
  • GlaxoSmithKline (Laxoberal)
  • Prestige Consumer Healthcare (ClearLax)

Newer entrants and generics are increasing market competition. Distribution channels span pharmacies, supermarkets, and online platforms.

Regulatory Landscape

In the United States, the Food and Drug Administration (FDA) regulates OTC laxatives under monographs. FT ClearLax Powder would require adherence to guidelines on active ingredients, labeling, and manufacturing standards.

In Europe, the European Medicines Agency (EMA) oversees similar regulations. Regulatory pathways for OTC status typically involve complying with the European Union's herbal and medicinal product standards.

Price Analysis and Trajectory

Current Price Range

  • Retail price of FT ClearLax Powder: USD 8 to USD 12 for a 30-sachet box (60 grams total).
  • Price per gram: USD 0.13 to USD 0.20.

Competitive Pricing Comparison

Product Price (USD) Pack Size Price per Gram (USD)
FT ClearLax 8 – 12 30 sachets 0.13 – 0.20
Dulcolax Powder 10 – 14 20 sachets 0.25 – 0.70
Phillips Stool Softener 9 – 13 20 sachets 0.45 – 0.65

Price Projection (2023-2028)

  • Price per gram is expected to decrease by 1-2% annually due to increased competition and generics.
  • Bulk packaging options could lower consumer prices further.
  • Premium formulations or added ingredients (e.g., flavored variants) could maintain higher price points.

Projected retail price for a 30-sachet pack in 2028:

Scenario Price Range (USD) Notes
Market-driven decline 6.50 – 9 Based on competitive pressure
Premium product positioning 10 – 13 For formulations with added benefits

Distribution and Price Strategies

  • Direct-to-consumer online sales could reduce distribution costs, enabling lower consumer prices.
  • Partnering with pharmacy chains can sustain higher margins and stabilize pricing.
  • Volume discounts and subscription models attract repeat customers.

Regulatory Impact on Pricing

  • Stringent regulations might increase manufacturing costs, limiting price reductions.
  • OTC marketing claims and compliance expenses influence retail pricing strategies.

Key Market Trends

  • Rising demand for natural and herbal laxatives influences formulation development.
  • Increasing online sales channels impact pricing flexibility.
  • Consumer preference shifts toward transparent ingredient lists may support premium pricing.

Key Takeaways

  • The global OTC laxatives market, including FT ClearLax Powder, grows at 4.5% CAGR and is worth USD 1.8 billion.
  • Price per gram is around USD 0.13–0.20; expected to decrease slightly over five years.
  • Competitive pressures, regulatory costs, and formulation trends influence pricing.
  • Distribution shifts to online commerce could enable lower retail prices.
  • Premium variants and natural formulations may sustain higher prices.

FAQs

How does the price of FT ClearLax compare to other laxatives?

FT ClearLax is typically priced lower than prescription-only laxatives like Dulcolax or Fleet enema, which are often USD 0.25–0.70 per gram.

Will regulatory changes affect the future pricing of FT ClearLax?

Yes. Stricter regulations can increase manufacturing costs, potentially limiting price drops and leading to higher retail prices.

Are online sales expected to impact FT ClearLax’s pricing?

Yes. Online channels generally offer lower prices due to reduced distribution costs, increasing pricing competition.

What trends might influence the price of OTC laxatives in the next five years?

Growing demand for natural ingredients, consumer preference for transparent labeling, and market competition are key factors.

Can product innovation sustain higher prices?

Introducing natural formulations, added flavoring, or other benefits could justify premium pricing in a competitive landscape.


References

[1] MarketsandMarkets. (2022). OTC laxatives market forecast. Retrieved from https://www.marketsandmarkets.com

[2] U.S. Food and Drug Administration. (2023). OTC drug review regulations. Retrieved from https://www.fda.gov

[3] European Medicines Agency. (2023). OTC regulation standards. Retrieved from https://www.ema.europa.eu

[4] Statista. (2023). OTC laxatives market size and growth. Retrieved from https://www.statista.com

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.